Related Experiment Video
Updated: Aug 11, 2026
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
Oncolytic herpes simplex virus vectors for the treatment of human breast cancer
1Department of Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. renbinliu@yahoo.com
Background:
Oncolytic herpes simplex virus (HSV) vectors can be used for cancer therapy as direct cytotoxic agents, inducers of anti-tumor immune responses, and as expressers of anti-cancer genes. In this study, the efficacy of HSV vectors, G47Delta and NV1023 were examined for the treatment of the human breast cancer.
Methods:
Human breast cancer MDA-MB-435 cells were cultured or implanted subcutaneously in BALB/c nude mice. The cells or tumors were inoculated with G47Delta or NV1023, and cell killing or inhibition of tumor growth determined. Both viruses contained the LacZ gene and expression in infected cells was detected with X-gal histochemistry.
Results:
G47Delta and NV1023 were highly cytotoxic to MDA-MB-435 cells in vitro at very low multiplicities of infection. X-gal staining of infected tumor cells in vitro and in vivo illustrated the replication and spread of both viruses. G47Delta and NV1023 inoculation inhibited tumor growth and prolonged mouse survival. Both vectors behaved similarly.
Conclusions:
Oncolytic HSV vectors, G47Delta and NV1023, were extremely effective at killing human breast cancer cells in vitro and in tumor xenografts in vivo. This novel form of cancer therapy warrants further investigation and consideration of clinical application.
Insights
Oncolytic herpes simplex virus (HSV) vectors G47Delta and NV1023 effectively killed human breast cancer cells in lab studies and animal models. These oncolytic HSV therapies show promise for future breast cancer treatment.
Area of Science:
- Oncolytic virotherapy
- Cancer gene therapy
- Herpes simplex virus (HSV) vectors
Background:
- Oncolytic HSV vectors offer multifaceted cancer treatment strategies: direct cell killing, immune response induction, and gene expression.
- Investigating the therapeutic potential of G47Delta and NV1023 HSV vectors against human breast cancer.
Purpose of the Study:
- To evaluate the efficacy of G47Delta and NV1023 oncolytic HSV vectors in treating human breast cancer.
- To assess the direct cytotoxic effects and tumor growth inhibition capabilities of these vectors.
Main Methods:
- Human breast cancer cells (MDA-MB-435) were cultured in vitro and implanted in mice for in vivo studies.
- Cells and tumors were treated with G47Delta or NV1023 HSV vectors; cell killing and tumor growth inhibition were measured.
- Viral replication and spread were visualized using X-gal histochemistry to detect LacZ gene expression.
Main Results:
- Both G47Delta and NV1023 demonstrated high cytotoxicity against MDA-MB-435 cells at low multiplicities of infection.
- In vitro and in vivo studies confirmed viral replication and spread within infected tumor cells.
- Treatment with G47Delta and NV1023 significantly inhibited tumor growth and prolonged survival in mice, with similar vector performance.
Conclusions:
- Oncolytic HSV vectors G47Delta and NV1023 are highly effective in eliminating human breast cancer cells both in vitro and in vivo.
- These findings support further research and potential clinical application of oncolytic HSV vectors as a novel breast cancer therapy.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...